Format

Send to

Choose Destination
J Hepatol. 2018 Aug;69(2):525-533. doi: 10.1016/j.jhep.2018.03.028. Epub 2018 Apr 11.

New trials and results in systemic treatment of HCC.

Author information

1
Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. Electronic address: mreig1@clinic.ub.es.
2
Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
3
Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), INSERMU1149 & Université Paris 7, Paris, France. Electronic address: prof.faivre@gmail.com.

Abstract

The design of prospective trials in hepatocellular carcinoma is a true challenge because the underlying condition of the liver, upon drug exposure, could interact with the specific course of carcinoma and influence overall outcome. The information generated by basic and clinical researchers provides the rationale for improving the prognosis of this complex disease. However, an additional challenge is interpreting emerging data in real time in order to integrate them into the design of further trials. Analysing recent results in detail may contribute to improving trial design and analysis, expediting the translation of a novel agent's potential benefit, assessed in prospective interventions, to clinical practice. This review summarises the data already known and discusses newly available results, along with ongoing systemic trials in hepatocellular carcinoma treatment.

KEYWORDS:

Clinical trials; Hepatocellular carcinoma; Systemic treatment

PMID:
29653122
DOI:
10.1016/j.jhep.2018.03.028

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center